-$0.07 EPS Expected for VBI Vaccines Inc. (NASDAQ:VBIV) This Quarter

Equities research analysts predict that VBI Vaccines Inc. (NASDAQ:VBIV) will report earnings per share of ($0.07) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for VBI Vaccines’ earnings, with estimates ranging from ($0.09) to ($0.05). VBI Vaccines posted earnings per share of ($0.05) during the same quarter last year, which would suggest a negative year over year growth rate of 40%. The business is scheduled to announce its next quarterly earnings report on Wednesday, May 5th.

On average, analysts expect that VBI Vaccines will report full year earnings of ($0.27) per share for the current financial year, with EPS estimates ranging from ($0.33) to ($0.24). For the next year, analysts forecast that the business will post earnings of ($0.13) per share, with EPS estimates ranging from ($0.29) to $0.05. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover VBI Vaccines.

VBI Vaccines (NASDAQ:VBIV) last issued its quarterly earnings data on Monday, March 1st. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). The business had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.44 million. VBI Vaccines had a negative return on equity of 36.69% and a negative net margin of 2,837.73%.

VBIV has been the subject of several recent analyst reports. Jefferies Financial Group initiated coverage on VBI Vaccines in a research note on Thursday, February 25th. They issued a “buy” rating and a $7.00 price target for the company. Zacks Investment Research lowered VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Saturday, March 6th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $5.90.

A number of large investors have recently bought and sold shares of the business. tru Independence LLC purchased a new stake in shares of VBI Vaccines in the fourth quarter valued at approximately $2,782,000. BlackRock Inc. grew its position in shares of VBI Vaccines by 7.8% in the fourth quarter. BlackRock Inc. now owns 13,175,944 shares of the biopharmaceutical company’s stock valued at $36,234,000 after purchasing an additional 948,860 shares in the last quarter. General American Investors Co. Inc. grew its position in shares of VBI Vaccines by 63.5% in the fourth quarter. General American Investors Co. Inc. now owns 1,635,785 shares of the biopharmaceutical company’s stock valued at $4,498,000 after purchasing an additional 635,185 shares in the last quarter. Swiss National Bank purchased a new stake in shares of VBI Vaccines in the fourth quarter valued at approximately $1,006,000. Finally, Creative Planning lifted its holdings in VBI Vaccines by 975.3% in the fourth quarter. Creative Planning now owns 352,087 shares of the biopharmaceutical company’s stock valued at $968,000 after acquiring an additional 319,344 shares during the last quarter. Institutional investors own 52.13% of the company’s stock.

Shares of VBIV stock opened at $2.94 on Wednesday. The stock has a market cap of $747.33 million, a PE ratio of -17.29 and a beta of 2.14. The business has a 50-day simple moving average of $3.06 and a 200-day simple moving average of $3.09. The company has a quick ratio of 8.95, a current ratio of 9.06 and a debt-to-equity ratio of 0.10. VBI Vaccines has a 52-week low of $1.18 and a 52-week high of $6.93.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

See Also: How to use beta for portfolio diversification

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.